^
Association details:
| Biomarker: | CCNE1 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) + adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
Published date:
04/01/2021
Excerpt:
...TNBCs that harbor either mutations in BRCA1/2 or overexpression of cyclin E are very sensitive to the growth inhibitory effects of AZD-1775 (Wee 1 kinase inhibitor) when used in combination with MK-4837 (PARP inhibitor)
DOI:
10.3390/cancers13071656
